THE EPISOUTH PLUS PROJECT

THE MEDITERRANEAN REGIONAL LABORATORY NETWORK (MRLN)

WP4 Training on West Nile and Biosafety II in the Laboratory
24-28 June 2013, Instituto de Salud “Carlos III”, Madrid, Spain

Kathleen Victoire\(^1\), Sabah Boufkhed\(^1\), Gulay Korukluoglu\(^2\)

\(^1\)Institut Pasteur, International Division, Paris, France
\(^2\)Turkish Public Health Institution, Dept. of Microbiology Reference Labs., Ankara, Turkey

and the WP4 Steering Team

on behalf of the EpiSouth Network

SEPTEMBER 2013
The EpiSouth Plus project is co-funded by the European Union DG-SANCO/EAHC and DEVCO/EuropeAid together with the participating national partner Institutions. The financial support of the Italian Ministry of Health and ECDC is also acknowledged.

The Project is led by the Italian National Institute of Health and counselled by an Advisory Board composed by EC, ECDC, WHO and other international experts.

The contents of this publication are the sole responsibility of the Italian National Institute of Health and can in no way be taken to reflect the views of the European Union.

The EpiSouth Plus project’s reports are freely available in the public domain (www.episouthnetwork.org) and may be used and reprinted without special permission; citation as to source, however, is required.


EPISOOUTH PLUS PROJECT OFFICE

**Project Leader**

Silvia Declich  
Istituto Superiore di Sanità – Italian National Institute of Health  
National Centre for Epidemiology, Surveillance and Health Promotion  
Rome, Italy  
e-mail: silvia.declich@iss.it

**WP1 Co-Leaders – Coordination of the project**

Maria Grazia Dente  
Istituto Superiore di Sanità – Italian National Institute of Health  
National Centre for Epidemiology, Surveillance and Health Promotion  
Rome, Italy  
e-mail: maria.grazia.dente@iss.it

Mondher Bejaoui  
Ministère de la Santé Publique  
Primary Health Care Directorate  
Tunis, Tunisia  
e-mail: mondher.bejaoui@rms.tn

**WP2 Co-Leaders – Dissemination of the project**

Massimo Fabiani/Valeria Alfonsi  
Istituto Superiore di Sanità – Italian National Institute of Health  
National Centre for Epidemiology, Surveillance and Health Promotion  
Rome, Italy  
e-mail: massimo.fabiani@iss.it  
e-mail: valeria.alfonsi@iss.it

Dragan Lausevic  
Institute of Public Health  
Centre for Disease Control and Prevention  
Podgorica, Montenegro  
e-mail: dragan.lausevic@ijzcg.me

**WP3 Leader - Evaluation of the project**

Giuseppe Salamina  
ASL TO1  
Torino, Italy  
e-mail: giuseppe.salamina@aslit01.it

**WP4 Co-Leader - Laboratory Network**

Kathleen Victoir  
Institut Pasteur  
Division International  
Paris Cedex, France  
e-mail: kathleen.victoir@pasteur.fr

Gulay Korukluoglu  
Public Health Institution of Turkey  
Laboratory of Virology  
Ankara, Turkey  
e-mail: gucank@gmail.com

**WP5 Co-Leader –Preparedness Plan and Risk Management**

Fernando Simon Soria/ Concepcion Martin de Pando  
Instituto de Salud Carlos III – Carlos III Health Institute  
National Epidemiology Centre  
Madrid, Spain  
e-mail: fisimon@isciii.es  
e-mail: cmartinpando@isciii.es

Djohar Hannoun  
Institut National de Santé Publique of Algeria  
Department of Health Information  
Alger, Algeria  
e-mail: hannound@yahoo.fr

**WP6 Co-Leader – Cross-border Epidemic Intelligence**

Philippe Barboza/Fatima Belghiti  
Institut de Veille Sanitaire – French Institute for Public Health Surveillance  
Department International and Tropical Diseases  
Saint Maurice Cedex, France  
e-mail: p.barboza@invs.sante.fr  
e-mail: f.belghiti@invs.sante.fr

Alex Leventhal/ Asa’d Ramlawi/ Mohamed Husein Adel Belbeisi/ Sari Hussein  
MECIDS - Middle East Consortium for Infectious Diseases Surveillance  
e-mail: alex.leventhal@moh.health.gov.il  
e-mail: ramlawi_asad@hotmail.com  
e-mail: fetp@wanadoo.jo  
e-mail: shusseini@sfcg.org

**WP7 Co-Leader – Facilitating IHR implementation**

Flavia Riccardo  
Istituto Superiore di Sanità – Italian National Institute of Health  
National Centre for Epidemiology, Surveillance and Health Promotion  
Rome, Italy  
e-mail: flavia.riccardo@iss.it

Pierre Nabeth  
World Health Organization  
Global Capacities Alert & Response (GCR)  
IHR Monitoring, Procedures & Information (MPI)  
Lyon, France  
e-mail: nabethp@who.int
THE EPISOUTH NETWORK

EPISOUTH PROJECT (2006-10)

In occasion of the Year of the Mediterranean (2005), a number of countries that share the Mediterranean ecosystem and therefore have common public health problems, agreed to develop the project “EpiSouth”, whose aim was to create a framework of collaboration on epidemiological issues in order to improve communicable diseases surveillance, communication and training in the Mediterranean region and South-East Europe.

The Project “EpiSouth” started in October 2006 with the financial support of the EU DG-SANCO together with the Italian Ministry of Health and has been closed in June 2010. As per June 2010, EpiSouth is a Network of 27 countries (9 EU and 17 non-EU countries plus 1 candidate to enlargement country). It is therefore the biggest inter-country collaborative effort in the Mediterranean region.

EPISOUTH PLUS PROJECT (2010-13)

A new phase of the EpiSouth Network activities has been approved and started on 15 October 2010 and is expected to last until 15 April 2013.

The new phase implies a shift of the Network’s activities to a wider approach. Building on the knowledge of regional gaps and needs identified during the first EpiSouth implementation in the fields of Epidemic Intelligence, Vaccine Preventable Diseases and Migrants, Cross Border Emerging Zoonoses and Training in field/applied epidemiology, the new EpiSouth Plus Project aims at contributing to the control of public health threats and other bio-security risks in the Mediterranean region and South-East Europe.

OBJECTIVE AND ORGANIZATION

The EpiSouth Plus project is aimed at increasing the health security in the Mediterranean area and South-East Europe by enhancing and strengthening the preparedness to common health threats and bio-security risks at national and regional levels in the countries of the EpiSouth Network in the framework of the International Health Regulations (IHR) implementation. The reinforcement of relations of trust in the region is an objective and an instrument in the scope of Project’s implementation.

Ensuring a successful response to this challenge requires a solid framework of collaboration and information exchange among the 27 participating Countries. To this purpose, Focal Points from each participating country have been appointed and asked for active involvement and collaboration in the project’s activities.

The project is organized in seven Work Packages (WP), jointly co-led by EU and non-EU countries. WP leaders work in strict contact with the corresponding WP Steering Team, while a Steering Committee, constituted by all WP leaders, and the Project General Assembly, constituted by all participants, are responsible for the general strategic decisions. Finally, an Advisory Board, constituted by representatives of
the collaborating institutions and external experts, provide support for the revision of relevant documents and recommendations.

ACTIVITIES

Apart from three transversal WPs (i.e., WP1-Coordination; WP2-Dissemination; WP3- Evaluation) the project’s activities are articulated in four WPs:

1) Establishment of a Mediterranean Regional Laboratories Network to facilitate common threats detection in the countries involved (WP4).

2) Promotion of common procedures in Generic Preparedness and Risk Management Plans among the countries involved (WP5).

3) Enhancing Mediterranean Early Warning Systems (EWS) and cross-border Epidemic Intelligence allowing alerts and Epidemic Intelligence information sharing among EpiSouth countries and developing interoperability with other European EW platform, especially EWRS, as forecast by the current EU legislation (WP6).

4) Facilitating IHR implementation through the production of a strategic document, with guidelines based on specific assessments for describing how national plans/legislations can interact with IHR requirements (WP7).
PLAN

1. INTRODUCTION ............................................................................................................. 5
   1.1. Objectives of the training ..................................................................................... 5
   1.2. Participants ........................................................................................................... 5

2. THE TRAINING .............................................................................................................. 6
   2.1. Theoretical part .................................................................................................... 6
   2.2. Practical part ....................................................................................................... 7

3. EVALUATION ............................................................................................................... 8
   3.1. Evaluation of the trainees ..................................................................................... 8
   3.2. Evaluation of the training .................................................................................... 9

CONCLUSION AND WRAP-UP ..................................................................................... 11

ANNEXES ....................................................................................................................... 13
Introduction

The second EpiSouth laboratory training session took place at the Instituto de Salud “Carlos III”, Madrid (Spain) from 24 to 28 June 2013. It has been organised by the WP4 team with the Laboratory of Arboviruses and imported viral diseases of the ISCIII and Philippe Dubois, consultant on Biosafety, previously WHO trainer.

1.1. Objectives of the Training

The objectives of this training were to improve the diagnosis and understanding of West Nile and the level of biosafety in the laboratories of the EpiSouth MRLN and to enhance the networking among participating laboratories. The biosafety modules were complementary to the modules discussed on the first training, but could be attended by new trainees.

For the Agenda, see Annex 1.

1.2. Participants

The WP4 requested the heads of laboratories that were represented during the first training to nominate the same trainee if possible. For the new participating laboratories, the criteria were the same than for the first training: permanent staff of the laboratory, active person working at the bench, English and/or French speaker, able to provide training to other laboratory members at the return in her/his laboratory.

The twenty laboratories (7 EU and 13 non-EU) that participated were:

<table>
<thead>
<tr>
<th>Country</th>
<th>Country</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albania</td>
<td>Italy (ass. lab*)</td>
<td>Palestine</td>
</tr>
<tr>
<td>Algeria</td>
<td>Jordan</td>
<td>Romania</td>
</tr>
<tr>
<td>Bosnia &amp; Herzegovina</td>
<td>Kosovo</td>
<td>Serbia</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>Lebanon</td>
<td>Spain</td>
</tr>
<tr>
<td>Cyprus</td>
<td>Libya</td>
<td>Tunisia</td>
</tr>
<tr>
<td>FYROM</td>
<td>Malta</td>
<td>Turkey</td>
</tr>
<tr>
<td>Greece</td>
<td>Montenegro</td>
<td></td>
</tr>
</tbody>
</table>

* The Italian laboratory member of the core group could not propose a trainee for the training, so one from the associated laboratory “Lazzaro Spallanzani” has been proposed to participate with the agreement of the EpiSouth coordination and the Italian lab part of the core group.

In the frame of the good collaboration and the optimisation of already existing expertise on West Nile, international experts, especially from the EuroWestNile project that is coordinated by the host laboratory, were involved to give lectures. The EpiSouth WP5 was also invited.

For the list of participants see Annex 2.
2. The training

As for the first training on Dengue and Biosafety, the training combined theoretical and practical courses related to the laboratory diagnosis of West Nile and Biosafety.1 Likewise, trainees worked in pairs during theoretical and practical courses and compared results from different available commercial serological diagnostic kits for West Nile diagnosis in order to address limits and differences between the techniques. The aim of this comparison analysis is to identify strengths and weaknesses of the different available kits and be able to choose (performance or price) the most adapted for the home situation. The training is finalised by a case study session.

Theoretical part

The global context of West Nile has been set by different experts; lectures on epidemiology, clinic, ecology, veterinary and laboratory-related lectures have been given.

A round table with international experts of the Region has been organised on the first day of the training so as to share experience and introduce the complex issue of the emergence of West Nile in the Mediterranean region. The aim of this round table was to discuss about how a country with no case of West Nile faces the first suspected case and how this country should get prepared to face the possible next outbreaks by organising a surveillance of West Nile. There was a focus on the laboratory point of view but the discussion was also about the other partners that the laboratory staff should include in case of a WN outbreak (role of the government/ officials/ Public Health institutions/etc. in the different countries, place of the veterinarians, of the entomologists, etc.).

The discussion was structured around 5 axes that have been introduced by different intervening experts:

First situation, a country with no experience in West Nile detection faces a possible first case

1. What happens when the apparition of the 1st suspected case of West Nile appears in the country? (Intervener: Anna Papa-Konidari, Aristotle University of Thessaloniki, Greece)

1 Note: The presentations of the training are available on the private area of the EpiSouth website in the ENWA WP4 section: https://nwa.episouthnetwork.org/index.php?tab=3&id_area=2066&topic=Training
2. What kind of investigation/outbreak team should be set-up for a case of a suspected WN outbreak? (*Intervener: Mari Paz Sanchez Seco, Instituto de Salud Carlos III, Spain*)

3. In a country that never faced an outbreak before, what is the set of minimum tools that a laboratory should have to support the diagnosis of WN? (*Intervener: Gülay Korukluoğlu, Turkish Public Health Institution, Turkey*)

*Now, the country is becoming endemic and it is decided to set-up a surveillance system.*

4. What experts should be part of a surveillance team? (*Intervener: Aykut Özkul, Ankara University*)

5. What are the new tools that a (future) reference laboratory should acquire? Technology updates? (*Intervener: Maria Rosaria Capobianchi, Istituto Nazionale per le Malattie Infettive (INMI) “L. Spallanzani”, Italy*)

A module on **case studies** has been organised at the end of the training to summarize and put into perspective what has been learnt throughout the week. This module has been more developed (4 hours instead of 2 hours and use of an interactive tool) during this second training upon request of the trainees at the end of the first training.

The **biosafety modules** were organised in two parts: a biorisk assessment module, including exercises on a computer-based tool and an interactive lecture (with video images) on facility design (BSL3) and maintenance.

### 2.1. **Practical part**

The objective of the practical course was to learn how to perform or to improve the West Nile laboratory diagnosis (molecular biology and serology).

The used laboratory protocols for PCR methods have been developed by the Spanish partners (ISCIII and CISA-INIA) and for serology kits were used.

**Real-time RT-PCR**

It enables the detection of West Nile virus DNA in acute phase samples and is the preferred molecular tool to detect West Nile virus early in the course of West Nile infection. Identification with this technique can distinguish the different serotypes. An “in-house” protocol and primers have been used for the multiplex PCR method used by the ISCIII laboratory and shared with the trainees.
**IgG and IgM ELISA**

As most of the laboratories used commercial kits to perform the serology of WN, WP4 asked the participating laboratories, before the training, what commercial kits were accessible in their country, in order to use these kits for the training. Except 2 laboratories that each used different kits difficult to access in all other participating countries, the laboratories were using the same 2 kits. Therefore, it has been decided to use these 2 kits and compare them for their sensitivity and specificity during the course. This to discuss the limits and strengths of these 2 kits, using a panel of well characterised sera from patients. The used panel has kindly been provided by the Greek laboratory of the MRLN (Anna Papa-Konidari, Aristotle University of Thessaloniki), also identified as a supportive laboratory for the MRLN.

Five sera were analysed by ten pairs of trainees. Each serum was tested twice by 2 different pairs of trainees (each pair using a different kit for IgG and IgM). The results obtained from the different kits and trainees have been discussed and analysed collectively. It appeared that the most expensive kit was also the most performant one.

3. **Evaluation**

3.1. **Evaluation of the trainees**

The efficiency of the training has been evaluated by a short test on biosafety/biorisk knowledge. As for the first training, the same test was done by the trainees on the first morning and on the last afternoon of the training week *(See Annex 3).*

*Graph 1* describes the level of knowledge of the trainees on biosafety and biorisk before and after the training. It shows that the level of the trainees was heterogeneous before and after the training but the level of all the trainees clearly improved: from 4 to 66% of good answers at the pre-test and from 60 to 100% of good answers (12 trainees over 17 had 100% of correct answers).
Graph 1: Improvement of the level of knowledge of the trainees on biosafety and biorisk before and after the training.

3.2. Evaluation of the Training

On the last afternoon of the training, an evaluation survey (see Annex 4) has been addressed to the trainees to evaluate the different modules of the training (see Graphs 2 to 5) and to assess their expectations for the future of the MRLN and EpiSouth network (see Table 1). A discussion completed this assessment.

All the trainees were very satisfied by the training (overall score of the quality: 4.5/5) and 100% of the trainees declared that the training met their expectations.

Regarding the sequencing module, during the discussion, there was also a great demand to have more time to focus on. This topic has been explored during this training, but as it is a vast topic and trainees had heterogeneous skills on the subject, it has been difficult to totally reach the expectations. At least, this has raised awareness towards this discipline and underlined the necessity of sequencing surveys to control the spread of the disease.

The Table 1 describes the perspectives and expectations of the trainees after the training and after the end of the project.

The trainees are expecting the continuation and sustainability of the MRLN after the project ends. Their top 3 expectations are respectively to improve capacity (mostly with training), to
exchange and share information and to extend the topics to other pathogens (emerging plus respiratory diseases have been mentioned).

Concerning their expectations for the possible next trainings, they would like more practice, an extended time or a reorganisation of the schedule to have an agenda including the next steps in WN diagnosis (IFA, seroneutralisation, culture). The seroneutralisation and cell culture remained a request. However due to i) the important number of participants ii) their heterogeneous background and level iii) the few having access to BSL3 facilities in their home situation, the possibility of organising such a training and its impact would remain very limited. Nevertheless, the IFA technique could be considered as a technique to be taught in a future training on WN.

Further requests were expressed concerning further training on the use of sequences and sequence analysis for molecular epidemiology of WN.

![Graph 1: Average representation of the results of the evaluation of the course (1= very good, 5= very bad)](image)

**Graph 1:** Average representation of the results of the evaluation of the course (1= very good, 5= very bad)

![Graph 2: Evaluation of the lectures of the external experts.](image)

**Graph 2:** Evaluation of the lectures of the external experts.
(1: very good → 5: very bad)

![Graph 3: Evaluation of the Biosafety modules.](image)

**Graph 3:** Evaluation of the Biosafety modules.
(1: very good → 5: very bad)

**Figure 1:** Average representation of the results of the evaluation of the course (1= very good, 5= very bad)

Overall students were satisfied with the course a point of improvement seemed to be the timing of the sessions (too less time for sequence analysis and too less time for practical work)

<table>
<thead>
<tr>
<th>Items of the questionnaire</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>How would you apply what you have learnt within the next 6 months?</td>
<td>14</td>
</tr>
<tr>
<td>Introduce / implement methods in the lab - Foster collaboration</td>
<td></td>
</tr>
</tbody>
</table>
Change / adapt methods already in place in the lab  6
Apply what have been learnt during the training  5
Share / transfer knowledge to lab colleagues  4

Do you have any idea to improve such training session?
More practice  5
Extend time period / Reorganise the schedule  5
Reallocate the timing  3
Other new techniques  3
More sequencing  2
Using more the experience of the trainees  2

What do you expect for a possible continuation of the Mediterranean Regional Laboratory Network and of the whole EpiSouth network?
Improve capacity  9
Exchange and share information  8
Extend to other pathogens  6
Sustain the Network  5
Organisation of EQA  3
Identification of supporting laboratory  2
Other *  5

* Other:
- Develop multi-centric project in this field ;
- The conscientisation of the European commission about the problem of: 1/ The emergence of some viral zoonosis due to Global climate change; 2/ The threat represented for the A. Albopictus colonization of the Mediterranean basin in relation to autochthonous transmission of Dengue fever, YFV ;
- Project about epidemiology, management data, share our knowledge and experience of cases ;
- Audiences will be very important to follow-up the application and the progress regarding to the topics that was submitted during this meeting ;
- The laboratory part has to find a new formula to work together (example: Create a website - interactive!) to put our questions, protocols, etc.

**Conclusion and wrap-up**

This second EpiSouth laboratory training has consolidated the trust and the networking among the laboratory staff from the whole Mediterranean and Balkans region that had participated to the first training and fostered the collaboration with the new members. The WP4 has succeeded in improving laboratory capacity by training staff on Biosafety and West Nile diagnosis. As a result of the evaluation of the first training, the number of practical modules and of interactive and group exercises has been increased. However, trainees persist to ask for more practice. But we feel that it is very important for the lab staff to be aware of the global context.
All the trainees wish to have a continuation of the network and its activities. In particular, they expect to have the occasion to continue to exchange information (such as protocols or experience) and to improve the capacities of their laboratory though training.
Annexes
# ANNEX 1: Agenda of the training

<table>
<thead>
<tr>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-10:00</td>
<td>09:00-10:00</td>
<td>09:00-10:00</td>
<td>09:00-10:00</td>
<td>09:00-10:00</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td>10:00-11:00</td>
<td>10:00-11:00</td>
<td>10:00-11:00</td>
<td>10:00-11:00</td>
</tr>
<tr>
<td>11:00-12:00</td>
<td>11:00-12:00</td>
<td>11:00-12:00</td>
<td>11:00-12:00</td>
<td>11:00-12:00</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>12:00-13:00</td>
<td>12:00-13:00</td>
<td>12:00-13:00</td>
<td>12:00-13:00</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>13:00-14:00</td>
<td>13:00-14:00</td>
<td>13:00-14:00</td>
<td>13:00-14:00</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>14:00-15:00</td>
<td>14:00-15:00</td>
<td>14:00-15:00</td>
<td>14:00-15:00</td>
</tr>
<tr>
<td>15:00-16:00</td>
<td>15:00-16:00</td>
<td>15:00-16:00</td>
<td>15:00-16:00</td>
<td>15:00-16:00</td>
</tr>
<tr>
<td>16:00-17:00</td>
<td>16:00-17:00</td>
<td>16:00-17:00</td>
<td>16:00-17:00</td>
<td>16:00-17:00</td>
</tr>
</tbody>
</table>

Legend:
- **General presentation and Evaluation**
- **Laboratory exercises**
- **Case scenarios**
- **Workshop**

- **WN in mosquitoes and birds**
- **WB in mosquitoes and birds**
- **ELISA**
- **PCR**
- **Background**
- **Laboratory diagnosis and surveillance**
- **Other cows**

**WN** - West Nile virus

**WS** - West Nile syndrome

**ELISA** - Enzyme-linked immunosorbent assay

**PCR** - Polymerase chain reaction

**WB** - Western blot

**Legend:**
- **General presentation and Evaluation**
- **Laboratory exercises**
- **Case scenarios**
- **Workshop**

- **WN in mosquitoes and birds**
- **WB in mosquitoes and birds**
- **ELISA**
- **PCR**
- **Background**
- **Laboratory diagnosis and surveillance**
- **Other cows**

**WN** - West Nile virus

**WS** - West Nile syndrome

**ELISA** - Enzyme-linked immunosorbent assay

**PCR** - Polymerase chain reaction

**WB** - Western blot

---

EpiSouth Plus WP4 – Training on West Nile and Biosafety II in the lab
Instituto de Salud Carlos III, Madrid, Spain – 24-28/06/2013

14 / 23
# ANNEX 2: List of participants

**Organisation:** Kathleen Viotier and Sabah Boukhed (International Division, Institut Pasteur)  
Gáyla Korkuğlu (Microbiology Department, Turkish Public Health Institution)  
with: Antonio Tenorio and the team of the Laboratory "Arboviruses and imported viruses" (ISCHI, Madrid)  
and: Philippe Dubois and Ingegerd Kallings (Biosafety expert)

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>First name</th>
<th>Last name</th>
<th>Organisation</th>
<th>Name of the institute, Name of the Laboratory</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALBANIA</td>
<td>Maja</td>
<td>KOTA</td>
<td>Institute of Public Health, Laboratory of Virology</td>
<td></td>
</tr>
<tr>
<td>ALGERIA</td>
<td>Assma</td>
<td>HACHID</td>
<td>Institut Pasteur d’Algerie - National Arena, Virology Department</td>
<td></td>
</tr>
<tr>
<td>ROUMANIA</td>
<td>Anamaria</td>
<td>HADZIANSANOVIC-MOHOI</td>
<td>Clinical Center University of Sarajevo, Institute of Clinical Microbiology</td>
<td></td>
</tr>
<tr>
<td>BULGARIA</td>
<td>Ira</td>
<td>CHRISTOVA</td>
<td>National Center of Infectious and Parasitic Diseases, N.I.R. on tick-borne infections</td>
<td></td>
</tr>
<tr>
<td>CYPRUS</td>
<td>Panayiota</td>
<td>HAJJIYIANNI</td>
<td>Nicola General Hospital, Immunology Laboratory</td>
<td></td>
</tr>
<tr>
<td>FYROM</td>
<td>Gotovska</td>
<td>BOSHEVSKA</td>
<td>Institute of Public Health of R. Macedonia, Laboratory for Virology and molecular diagnostics</td>
<td></td>
</tr>
<tr>
<td>GREECE</td>
<td>Eipida</td>
<td>QAYANA</td>
<td>Aristotle University of Thessaloniki, Medical School, Department of Microbiology</td>
<td></td>
</tr>
<tr>
<td>ITALY</td>
<td>Monica</td>
<td>PARENTI</td>
<td>Azienda Ospedaliera di Padova (Padua University Hospital), U.O.C. Microbiologia Virologia</td>
<td></td>
</tr>
<tr>
<td>JORDAN</td>
<td>Mohamed</td>
<td>SHAHI</td>
<td>Central Public Health Laboratory</td>
<td></td>
</tr>
<tr>
<td>KOSOVO</td>
<td>Xhevat</td>
<td>KAPI</td>
<td>National Institute of Public Health of Kosovo, Department of Microbiology</td>
<td></td>
</tr>
<tr>
<td>MALTA</td>
<td>Claire</td>
<td>MUSCAT</td>
<td>Mater Dei Hospital, Pathology Department, Virology Laboratory</td>
<td></td>
</tr>
<tr>
<td>MONTENEGRO</td>
<td>Zejla</td>
<td>ZEBOVIC</td>
<td>Institute of Public Health, Center for Medical Microbiology, Department for Virology and Serology</td>
<td></td>
</tr>
<tr>
<td>ROMANIA</td>
<td>Ani Ionica</td>
<td>GUTAR</td>
<td>National Institute for Research and Development in Microbiology and Immunobiology (CIEIM), Laboratory for water-borne infections</td>
<td></td>
</tr>
<tr>
<td>SERBIA</td>
<td>Slobica</td>
<td>KRESIC-ADROVIC</td>
<td>Institute of Virology, Vaccines and AVA, &quot;Tbilisi&quot;, National Reference Laboratory for Arboviruses</td>
<td></td>
</tr>
<tr>
<td>SPAIN</td>
<td>Marcelo</td>
<td>SALVATORE ROSSI</td>
<td>Institute of Health &quot;Carlos III&quot; (ISCHI), Laboratory of Arbovirus and Imported Viruses</td>
<td></td>
</tr>
<tr>
<td>TUNISIA</td>
<td>Rashed</td>
<td>HoSSGA</td>
<td>Institut Pasteur de Tunis, Laboratory of Clinical Virology</td>
<td></td>
</tr>
<tr>
<td>TURKEY</td>
<td>Irem</td>
<td>DURMAZ</td>
<td>Turkish Public Health Institution, Department of Microbiology Reference Laboratories, Virology Laboratory</td>
<td></td>
</tr>
</tbody>
</table>

## TRAINERS

**Lecturers**

<table>
<thead>
<tr>
<th>Country</th>
<th>First Name</th>
<th>Last Name</th>
<th>Organisation</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRANCE</td>
<td>Christophe</td>
<td>BATEJAT</td>
<td>Institut Pasteur</td>
<td>Co-instructor and moderator</td>
</tr>
<tr>
<td>FRANCE</td>
<td>Philippe</td>
<td>DUBOIS</td>
<td>Consultation on Quality and Biosafety</td>
<td>Co-instructor and moderator</td>
</tr>
<tr>
<td>GREECE</td>
<td>Anna</td>
<td>PAPAKONIDARI</td>
<td>Aristotle University of Thessaloniki, Medical School, Department of Microbiology</td>
<td>Co-instructor and moderator</td>
</tr>
<tr>
<td>ITALY</td>
<td>Maria Rosaria</td>
<td>CAPOBIANCHI</td>
<td>Istituto Nazionale per la Malattie Infettive - INMI</td>
<td>&quot;L. Spallanzani&quot;</td>
</tr>
<tr>
<td>TURKEY</td>
<td>Aykut</td>
<td>GÖKÜL</td>
<td>Department of Virology - Faculty of Veterinary Medicine - Ankara University</td>
<td>Staff for the workshop</td>
</tr>
</tbody>
</table>

### Spanish team and experts

<table>
<thead>
<tr>
<th>Country</th>
<th>First Name</th>
<th>Last Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPAIN - ISCHI</td>
<td>Antonio</td>
<td>TENORIO</td>
<td>Coordinator, Centro Nacional de Microbiología, Laboratorio de Arbovirus y enfermedades importadas</td>
</tr>
<tr>
<td>SPAIN - ISCHI</td>
<td>Carlos</td>
<td>CURIA MARTINEZ</td>
<td>Coordinator, Centro Nacional de Microbiología, Laboratorio de Arbovirus y enfermedades importadas</td>
</tr>
<tr>
<td>SPAIN - ISCHI</td>
<td>Fernando</td>
<td>DE ORPY</td>
<td>Coordinator, Centro Nacional de Microbiología, Laboratorio de Arbovirus y enfermedades importadas</td>
</tr>
<tr>
<td>SPAIN - ISCHI</td>
<td>Leticia</td>
<td>FRANCO</td>
<td>Coordinator, Centro Nacional de Microbiología, Laboratorio de Arbovirus y enfermedades importadas</td>
</tr>
<tr>
<td>SPAIN - ISCHI</td>
<td>Maria Paz</td>
<td>SANCHEZ-GECO</td>
<td>Coordinator, Centro Nacional de Microbiología, Laboratorio de Arbovirus y enfermedades importadas</td>
</tr>
<tr>
<td>SPAIN - ISCHI</td>
<td>Ana</td>
<td>VAZQUEZ</td>
<td>Coordinator, Centro Nacional de Microbiología, Laboratorio de Arbovirus y enfermedades importadas</td>
</tr>
<tr>
<td>SPAIN - ISCHI</td>
<td>Angel</td>
<td>ZABALLOS</td>
<td>Coordinator, Centro Nacional de Microbiología, Laboratorio de Arbovirus y enfermedades importadas</td>
</tr>
<tr>
<td>SPAIN - CIAHIA</td>
<td>Jovita</td>
<td>FERNANDEZ</td>
<td>CIAHIA - Instituto Nacional de Investigaciones y Experimentaciones Agronómicas y Forestales, Centro de Investigación en Salud Animal, Emergent y transboundary diseases</td>
</tr>
<tr>
<td>SPAIN - CIAHIA</td>
<td>Miguel Angel</td>
<td>JIMENEZ</td>
<td>CIAHIA - Instituto Nacional de Investigaciones y Experimentaciones Agronómicas y Forestales, Centro de Investigación en Salud Animal, Emergent and transboundary diseases</td>
</tr>
<tr>
<td>SPAIN - EBD-CSIC</td>
<td>Ramón</td>
<td>SORIGUER</td>
<td>EBD-CSIC - Entidades Biológicas de Defensa - Spanish Council for Scientific Research</td>
</tr>
</tbody>
</table>

## EPISOUTH PLUS WP4 TEAM

<table>
<thead>
<tr>
<th>Country</th>
<th>First Name</th>
<th>Last Name</th>
<th>Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRANCE - IP</td>
<td>Kathleen</td>
<td>VICTOR</td>
<td>Institut Pasteur, International Division</td>
</tr>
<tr>
<td>FRANCE - IP</td>
<td>Sabah</td>
<td>BOUKHED</td>
<td>Institut Pasteur, International Division</td>
</tr>
<tr>
<td>TURKEY</td>
<td>Gáyla</td>
<td>KORKUĞLU</td>
<td>Turkish Public Health Institution, Department of Microbiology</td>
</tr>
</tbody>
</table>
ANNEX 4: Pre-test (and Final test) to assess the progress made during the training

Biorisk Management

Pre-Course Assessment

<table>
<thead>
<tr>
<th>Your name:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Your country:</td>
</tr>
<tr>
<td>Your email:</td>
</tr>
<tr>
<td>Date:</td>
</tr>
</tbody>
</table>

Pre-course assessment score:

1. The term “laboratory biorisks” integrates two principal ideas. What are they? Please also try to define each of these two concepts.

2. Which of the following organizations has published the international standard for Laboratory Biorisk Management?
   - a. European Committee for Standardization (CEN)
   - b. Food and Agriculture Organization (FAO)
   - c. International Standards Organization (ISO)
   - d. World Health Organization (WHO)
   - e. World Organisation for Animal Health (OIE)
### Bi前三 Management

3. Describe the purpose of the international standard for Laboratory Biorsisk Management. Why do you think it is important?

4. To implement a Laboratory Biorsisk Management system, a laboratory should address which three specific processes?
   a. Risk Groups, Safety Levels, Equipment Maintenance
   b. Assessment, Mitigation, Performance
   d. Personal Protective Equipment, Biosafety Cabinets, Decontamination

5. Define risk in words.

6. Which mathematical definition of risk is most correct?
   a. Risk = function (likelihood, consequences)
   b. Risk = hazard x threat x vulnerability
   c. Risk = probability x consequences x vulnerability
   d. Risk = function (consequences, vulnerability)
7. What is the difference between a **hazard** and a **threat**? Define these concepts in words.

**Hazard:**

**Threat:**

8. What are the four categories of mitigation control measures?

   a. Risk assessment, engineering controls, practices and procedures, administrative controls
   b. Engineering controls, practices and procedures, administrative controls, personal protective equipment
   c. Personal protective equipment, engineering controls, administrative controls, decontamination methodologies
   d. Risk groups, biosafety levels, biosafety cabinets, waste management

9. In general, what is the first method to consider to reduce laboratory biorisks? Choose only one.

   a. Biosafety cabinets
   b. Personal protective equipment
   c. Elimination or substitution
   d. Decontamination methods
   e. Good laboratory practices
10. Describe what performance means in relation to biorisk management?

11. What are the **three** main components of performance?
   - a. Organization, staffing, management oversight
   - b. Facilities, equipment, procedures
   - c. Standard operating procedures, good laboratory practices, management oversight
   - d. Control, assurance, improvement
   - e. Responsibility, staffing, financial resources

12. What does "PDCA" stand for in a quality management system?
   - a. Plan, decontamination, clean-up, assessment
   - b. Preliminary demonstration of comprehensive activity
   - c. Pre-assessment, decontaminate, call for assistance, post-assessment
   - d. Precise decision criteria analysis
   - e. Plan, do, check, act

13. Why do you think PDCA is important?
ANNEX 5: Questionnaire for the trainees to assess the training

Training on West Nile and Biosafety II in the Lab
24-28 June 2013, Instituto de Salud “Carlos III” (Spain)

Organisation team:
Kathlen Victor and Sabah Boukhed
Gulay Korukluoglu (WP4) International Division, Institut Pasteur
Antonio Tenorio and his team (WP4) Microbiology Department, Turkish Public Health Institution
Philippe Dubois (Lab) Unit of Arboviruses and Imported viral diseases
(Biosafety) Consultant

EVALUATION OF THE TRAINING

A. To evaluate the quality of this training, we kindly ask you to rate the following items of the training

1 → VERY GOOD  5 → VERY BAD

LECTURES OF EXTERNAL EXPERTS

Additional comments or advises for the lectures of external experts:
LABORATORY PRACTICAL SESSIONS

Additional comments or advises for the laboratory practical sessions:

BIOSAFETY MODULES
Additional comments or advises for the biosafety modules:

SEQUENCING MODULES

Additional comments or advises for the sequencing modules:

B. Did the training met your expectations? (circle your answer)  Yes  No  Don’t know

If the training did not met your expectations: what could have been improved? What was missing?
C. How would you apply what you have learnt within the next 6 months?


D. Do you have any idea to improve such training session?


E. What do you expect for a possible continuation of the Mediterranean Laboratory network?


F. What do you expect for an possible continuation of the whole EpiSouth network?


Any comment or remark?